• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急诊科常规氧疗阶段高流量鼻导管失败预测。

Failure Prediction of High-Flow Nasal Cannula at the Conventional Oxygen Therapy Phase in the Emergency Department.

机构信息

Department of Emergency Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.

Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea.

出版信息

Respiration. 2024;103(8):488-495. doi: 10.1159/000540004. Epub 2024 Jun 22.

DOI:10.1159/000540004
PMID:38934166
Abstract

INTRODUCTION

The use of high-flow nasal cannula (HFNC) in patients with acute hypoxemic respiratory failure has been increasing in the emergency department (ED). However, studies are lacking on the prediction of HFNC failure before therapy initiation in the ED. We investigated whether the existing indices, such as the ratio of pulse oximetry oxygen saturation/fraction of inspired oxygen to respiratory rate (ROX) and ratio of ROX index to heart rate (ROX-HR), can accurately predict HFNC failure at the conventional oxygen therapy phase in the ED.

METHODS

This retrospective single-center study included patients treated with HFNC in the ED. The ROX and ROX-HR indices were calculated before initiating HFNC. An estimated fraction of inspired oxygen was used for conventional oxygen therapy. We plotted each index's receiver operating characteristics curve and calculated the area under the curve (AUC) for diagnostic capacity. The optimal cutoff values were assessed using the Youden index. The primary outcome was HFNC failure, defined as intubation in the ED.

RESULTS

Among the 97 included patients, 25 (25.8%) failed HFNC therapy in the ED. The ROX and ROX-HR indices measured before initiating HFNC showed AUCs of 0.709 and 0.754, respectively. A ROX index of <5.614 and a ROX-HR index of <6.152 were associated with a high risk of intubation, even after correcting for confounding variables.

CONCLUSION

The ROX and ROX-HR indices measured before initiating HFNC provide a relatively fair predictive value of HFNC failure in the ED.

摘要

简介

在急诊科(ED)中,高流量鼻导管(HFNC)在治疗急性低氧性呼吸衰竭患者中的应用正在增加。然而,在 ED 开始治疗之前,关于 HFNC 治疗失败的预测研究还很缺乏。我们研究了在 ED 的常规氧疗阶段,现有的指数,如脉搏血氧饱和度/吸入氧分数与呼吸率的比值(ROX)和 ROX 指数与心率的比值(ROX-HR),是否能准确预测 HFNC 治疗失败。

方法

这是一项回顾性的单中心研究,包括在 ED 接受 HFNC 治疗的患者。在开始 HFNC 治疗之前,计算 ROX 和 ROX-HR 指数。使用估计的吸入氧分数进行常规氧疗。我们绘制了每个指数的接收者操作特征曲线,并计算了诊断能力的曲线下面积(AUC)。使用 Youden 指数评估最佳截断值。主要结局是 HFNC 治疗失败,定义为 ED 内插管。

结果

在 97 例纳入的患者中,有 25 例(25.8%)在 ED 内 HFNC 治疗失败。在开始 HFNC 治疗之前测量的 ROX 和 ROX-HR 指数的 AUC 分别为 0.709 和 0.754。ROX 指数<5.614 和 ROX-HR 指数<6.152 与插管风险增加相关,即使在校正了混杂因素后也是如此。

结论

在开始 HFNC 治疗之前测量的 ROX 和 ROX-HR 指数对 ED 中 HFNC 治疗失败具有相对较好的预测价值。

相似文献

1
Failure Prediction of High-Flow Nasal Cannula at the Conventional Oxygen Therapy Phase in the Emergency Department.急诊科常规氧疗阶段高流量鼻导管失败预测。
Respiration. 2024;103(8):488-495. doi: 10.1159/000540004. Epub 2024 Jun 22.
2
Retrospective evaluation of the respiratory rate-oxygenation index to predict the outcome of high-flow nasal cannula oxygen therapy in dogs (2018-2021): 81 cases.回顾性评估呼吸频率-氧合指数预测犬高流量鼻导管氧疗结局(2018-2021 年):81 例。
J Vet Emerg Crit Care (San Antonio). 2024 May-Jun;34(3):252-261. doi: 10.1111/vec.13373. Epub 2024 May 6.
3
Using the ROX Index to Predict Treatment Outcome for High-Flow Nasal Cannula and/or Noninvasive Ventilation in Patients With COPD Exacerbations.使用 ROX 指数预测 COPD 加重患者使用高流量鼻导管和/或无创通气的治疗结局。
Respir Care. 2024 Aug 24;69(9):1100-1107. doi: 10.4187/respcare.11544.
4
Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index.预测高流量鼻导管吸氧对低氧性呼吸衰竭肺炎患者的疗效:ROX指数的应用价值。
J Crit Care. 2016 Oct;35:200-5. doi: 10.1016/j.jcrc.2016.05.022. Epub 2016 May 31.
5
Ratio of Oxygen Saturation to Inspired Oxygen, ROX Index, Modified ROX Index to Predict High Flow Cannula Success in COVID-19 Patients: Multicenter Validation Study.氧饱和度与吸入氧比值、ROX 指数、改良 ROX 指数预测 COVID-19 患者高流量鼻导管通气成功的多中心验证研究。
West J Emerg Med. 2023 Apr 28;24(3):511-521. doi: 10.5811/westjem.58311.
6
Respiratory rate‑oxygenation (ROX) index for predicting high-flow nasal cannula failure in patients with and without COVID-19.用于预测 COVID-19 患者和非 COVID-19 患者高流量鼻导管失败的呼吸频率-氧合(ROX)指数。
Am J Emerg Med. 2024 Jan;75:53-58. doi: 10.1016/j.ajem.2023.09.036. Epub 2023 Oct 14.
7
ROX index and SpO2/FiO2 ratio for predicting high-flow nasal cannula failure in hypoxemic COVID-19 patients: A multicenter retrospective study.ROX 指数和 SpO2/FiO2 比值预测低氧血症 COVID-19 患者高流量鼻导管治疗失败的多中心回顾性研究。
PLoS One. 2022 May 12;17(5):e0268431. doi: 10.1371/journal.pone.0268431. eCollection 2022.
8
Can the ROX index predict high-flow nasal cannula failure in children under 2 with lower respiratory tract infection?ROX指数能否预测2岁以下下呼吸道感染儿童的高流量鼻导管吸氧失败?
Pediatr Pulmonol. 2024 May;59(5):1246-1255. doi: 10.1002/ppul.26895. Epub 2024 Feb 2.
9
Comparison of ROX index (SpO/FIO ratio/respiratory rate) with a modified dynamic index incorporating PaO/FIO ratio and heart rate to predict high flow nasal cannula outcomes among patients with acute respiratory failure: a single centre retrospective study.比较 ROX 指数(SpO/FIO 比值/呼吸频率)与改良的动态指数(包括 PaO/FIO 比值和心率),以预测急性呼吸衰竭患者使用高流量鼻导管的结局:一项单中心回顾性研究。
BMC Pulm Med. 2022 Sep 16;22(1):350. doi: 10.1186/s12890-022-02121-9.
10
An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy.呼吸频率与氧合指数联合预测经鼻高流量治疗结局。
Am J Respir Crit Care Med. 2019 Jun 1;199(11):1368-1376. doi: 10.1164/rccm.201803-0589OC.

引用本文的文献

1
Efficacy of High Flow Nasal Cannula in the Treatment of Patients with COVID-19 with Acute Respiratory Distress Syndrome: Results of Single Centre Study in Vietnam.高流量鼻导管在治疗新型冠状病毒肺炎合并急性呼吸窘迫综合征患者中的疗效:越南单中心研究结果
Pulm Ther. 2024 Dec;10(4):451-468. doi: 10.1007/s41030-024-00272-0. Epub 2024 Oct 18.